Thalomid Capsule
NDC Package 59572-210-95
Package Information
Thalomid (thalidomide) capsules is a medication used to treat or prevent certain skin conditions related to Hansen's disease, once known as leprosy (erythema nodosum leprosum). This formulation utilizes a capsule delivery system. Marketed by Celgene Corporation, this product is identified by NDC 59572-210 and is authorized under FDA application NDA020785.
Identification & Billing
- RxCUI: 200390 - thalidomide 50 MG Oral Capsule
- RxCUI: 213360 - Thalomid 50 MG Oral Capsule
- RxCUI: 213360 - thalidomide 50 MG Oral Capsule [Thalomid]
- RxCUI: 360176 - thalidomide 100 MG Oral Capsule
- RxCUI: 360177 - thalidomide 200 MG Oral Capsule
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 59572 - Celgene Corporation
- 59572-210 - Thalomid
- 59572-210-95 - 5 BLISTER PACK in 1 BOX / 28 CAPSULE in 1 BLISTER PACK (59572-210-15)
- 59572-210 - Thalomid
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 59572-210-95 identifies a specific commercial package of 5 blister pack in 1 box / 28 capsule in 1 blister pack (59572-210-15) of Thalomid, a human prescription drug labeled by Celgene Corporation. This product is billed for "EA" each discreet unit and contains an estimated amount of 5 billable units per package. This capsule is formulated for oral use and contains thalidomide as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Celgene Corporation on June 20, 2003. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
This medication is used to treat or prevent certain skin conditions related to Hansen's disease, once known as leprosy (erythema nodosum leprosum). Thalidomide is also used to treat a certain type of cancer (multiple myeloma). It works in Hansen's disease by reducing swelling and redness (inflammation). It also reduces the formation of blood vessels that feed tumors.
How is this Celgene Corporation product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 59572021095. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 5 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.